Under construction – not a live service
Sign in
Taking people in ItalyNo phase

An Observational Study on Epithelioid Sarcoma

Key facts

Where
Bologna, Candiolo, Meldola, Milan, Padova, Palermo, Prato, Roma, and Rozzano, ItalySee the 11 sites

Where in Italy

  • Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal TumorsBologna, ItalyTaking people
  • Fondazione del Piemonte per l'Oncologia IRCC CandioloCandiolo, ItalyTaking people
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)Meldola, ItalyTaking people
  • Fondazione IRCCS INT - MilanoMilan, ItalyTaking people
  • Istituto Europeo di OncologiaMilan, ItalyTaking people
  • IRCCS Istituto Oncologico Veneto (IOV)Padova, ItalyTaking people
  • Azienda Ospedaliera Universitaria Paolo GiacconePalermo, ItalyTaking people
  • Ospedale Misericordia e Dolce Ist. Toscano Tumori, Az. USL4Prato, ItalyTaking people
  • Campus BiomedicoRoma, ItalyTaking people
  • Istituti Fisioterapici Ospitalieri di RomaRoma, ItalyTaking people
  • Istituto Clinico HumanitasRozzano, ItalyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Italian Sarcoma Group
Trial code
NCT03099681
Record updated
18 November 2025
Original description
Prospective Italian study aimed to provide a description of the population affected by Epithelioid Sarcoma (ES)Read full original descriptionShow less

Epithelioid Sarcoma. An Observational Study

Prospective Italian study aimed to provide a description of the population affected by Epithelioid Sarcoma (ES)

Inclusion: Histological diagnosis of epithelioid sarcoma according to 2014 World Health Organization (WHO) classification, performed on biopsy or surgical specimen; Signed informed consent; Adequate patient compliance to treatment or follow up; No age limit.

Exclusion: Other malignancies within past 5 years, with exception of carcinoma in situ of the cervix and basocellular skin cancers treated with eradicating intent; Impossibility to ensure adequate compliance.

ClinicalTrials.gov NCT03099681